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Major depressive disorder (MDD) contributes significantly to morbidity, disability, and decreased 
quality of life, despite the expansion of treatment options. This, in part, is caused by a lack of valid, applicable, 
and reliable biomarkers to predict the risk, treatment response, and prognosis of depression. In recent years, the 
anterior cingulate cortex, in particular pars subgenual (sgACC), has received much attention due to its potential 
utilization as a neural endophenotype for depression. This essay discusses the functional activity of sgACC, 
mostly by functional magnetic resonance imaging, in relation to predicting risk for developing depression, 
predicting patient response-to-treatment, and eventually, to creating a platform for the personalized psychiatric 
approach to each patient. The caveats and conditions need to be met are also discussed, in order to firmly 
establish sgACC activity as a valid biomarker for depression. 
 




Walaupun teknologi kedokteran berkembang amat pesat, gangguan depresi mayor masih merupakan 
salah satu penyebab utama terjadinya morbiditas, disabiltas, dan penurunan kualitas hidup. Hal ini disebab-
kan salah satunya karena belum ada penanda biologi yang valid dan reliabel yang dapat diaplikasikan untuk 
meramalkan risiko terjadinya depresi pada populasi, sekaligus untuk memprediksi respons terhadap terapi 
dan prognosisnya. Korteks singulatus anterior pars subgenual (sgACC) saat ini sedang diteliti secara intensif 
karena potensinya untuk bertindak sebagai endofenotip untuk depresi. Tulisan ini akan membahas aktivitas 
fungsional sgACC yang diukur terutama dengan fMRI--dalam peranannya untuk memprediksi risiko, respons, 
dan prognosis depresi. Hal ini dapat dijadikan dasar sebagai pendekatan personal untuk tiap pasien depresi. 
Selanjutnya, akan dibahas juga tentang kelemahan dan tantangan yang dihadapi sebelum menetapkan sgACC 
sebagai penanda biologis rutin untuk depresi. 
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INTRODUCTION 
Major depressive disorder (MDD) is 
one of the leading causes of years lived 
with disability, with a high relapse rate and 
lifetime prevalence of 15% (1). Socioeco-
nomically, it is a costly and socially impair-
ing disorder (2).  In clinics, MDD diagnosis 
is generally made based on the DSM-V (3). 
There have to be at least five of nine crite-
ria of depressive symptoms, including sad-
ness, anhedonia, and somatic disturbances, 
with a duration longer than 2 weeks. There 
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are many treatments available for depres-
sion, ranging from cognitive behavioral 
therapy to antidepressant drugs with vari-
ous mechanisms. However, despite the 
extensive, rapidly-expanding development 
in psychopharmacology, up to one-third 
patients continued to have persistent 
symptoms even after a full course of 
treatment (4). This happens because, at least 
in part, the therapy for depression is chosen 
empirically based on clinical presentation, 
which actually consists of a spectrum with 
no distinctive line between subtypes (5). A 
therapy for depression, as well as for other 
medical conditions, ideally must be 
adjusted individually, since every patient 
has their unique phenotype, resulting from 
variability in genetic predisposition to 
environmental factors (6). 
In this context, identifying a biomarker 
would be beneficial. A biomarker could 
provide clear and distinctive insight into 
diagnosis, risk factors, or prognostic re-
sponse to a therapy (7). It would be even 
more beneficial if the biomarker itself is 
involved in the pathological pathway be-
cause clinicians would be able to adminis-
ter a targeted-therapy rather than the empir-
ical ones. By identifying biomarkers in de-
pression, a more individualised therapy can 
be assigned, which eventually would in-
crease the success rate of the treatment. (8, 9) 
The difficulty in finding a suitable can-
didate for depression biomarker is its com-
plexity in term of the pathogenesis. Depres-
sion is multifactorial, where extensive in-
teractions take place in the neural circuitry 
(10). Another caveat is the difficulty to de-
tect subclinical cases, which is partially due 
to mental-health illiteracy of the society in 
seeking help for treating the mental 
disorders, besides becuase the diagnosis of 
MDD often requires clear and full-blowing 
symptoms that increases the threshold of 
clinical detection (11). When a patient 
presents with full-spectrum symptoms, the 
opportunity to spot any subclinical 
biomarker to predict population-at-risk 
would then be missed. 
After its introduction, about two dec-
ades ago, the utilization of functional mag-
netic resonance imaging (fMRI) has be-
come numerous both in clinical and re-
search setting. The use of fMRI in depict-
ing brain activity provides a better insight 
into the pathogenesis of depression in a 
dynamic way, and potentially, could serve 
as a reliable biomarker.  Subgenual anterior 
cingulate cortex (sgACC) is a part of the 
cingulate cortex below the genu of corpus 
callosum (hence the name, subgenual). 
Early lesion studies in animals (12, 13) 
suggested that sgACC is associated with 
the modulation of emotional behavior. 
Case-controlled structural neuroimaging in 
human studies have found a significant 
reduction in the grey matter volume of the 
anterior cingulate cortex among MDD 
patients (14, 15, but see 16). However, it has to be 
noted that psychiatric disorders, including 
depression, are multifactorial; they occur 
because of gene-environment interaction in 
each individual (6). Therefore, it would be 
more reasonable to search for functional 
biomarker rather than structural, since 
functional biomarkers are arguably more 
representative in reflecting the complex 
interaction of environment, neural 
endophenotypes, and genetic traits.  
Despite criticisms around fMRI utili-
zation, it has been enabling clinicians and 
researchers to acquire the impression of 
local field potential within any particular 
region of the brain (17, 18). In identifying the 
sgACC activity described above, fMRI is 
more superior to other neuroimaging tech-
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niques, such as electroencephalography in 
terms of spatial resolution, and positron 
emitting tomography (PET) in terms of in-
vasiveness and safety. This superiority pos-
its fMRI as a state-of-the-art modality in 
cognitive neuroscience today, evidenced by 
the abundance of fMRI-based research pub-
lications. However, when interpreting fMRI 
findings, it should be noted that fMRI does 
not display the direct neural activity. Ra-
ther, it reflects the vascular dynamic in re-
sponse to local field potentiation within a 
certain area of the brain (17).  
This essay focuses on the functional 
activity of sgACC in (1) predicting the risk 
factor of developing depression, and (2) 
predicting the treatment response.   
In line with studies about volumetric 
change in sgACC (19), association between 
the functional activity and the risk of suf-
fering depression in adolescence has also 
been shown. Masten, et al.  (20) in a small-
sampled cohort study (N=20, mean 
age=13) examined the relationship between 
sgACC activity during ostensible peer re-
jection (using a computer simulation) and 
the level of depressive symptoms during 
the following year. They found that greater 
sgACC activity elicited during the simula-
tion was associated with increases of de-
pressive symptoms at follow-up examina-
tion. This study has elegantly summed up 
the interaction between negative environ-
mental stimuli (peer rejection) and an endo-
phenotype (sgACC blood oxygen level-
dependent [BOLD] increase) in increasing 
the risk of depression. The small sample 
size, however, limited its power and gener-
alisability in larger population.  
The heritability nature of depression 
has been well known (10).  Gotlib, et al. (21) 
conducted an experiment using a reward-or
-punish game simulation involving 13 nev-
er-disordered daughters of mothers with 
history of recurrent depression and 13 age-
matched control subjects. They found that, 
when punishment was given, the subjects 
with familial history of depression had 
greater activation in the ACC than the con-
trol group. This study reinforces the crucial 
role of ACC activity when faced with neg-
ative environmental stressor and associates 
it with the risk factor of developing depres-
sion, as well as confirming the heritability 
of depression by identifying a potential en-
dophenotype.  
The study about the importance of 
functional sgACC activity in identifying at-
risk population is still ongoing. 
Methodological and conceptual 
considerations have to be taken into 
account before the integration of these 
findings into clinical settings (22). 
In terms of predicting the response to 
treatment, the original notion originated 
from positron-emitting tomography (PET) 
study (23). Due to the invasiveness and the 
risk of PET, there was a shift of functional 
neuroimaging study toward fMRI-based 
research.  
To date, across numbers of studies, the 
increasing in sgACC activity has been as-
sociated with good outcome when treated 
with pharmacological antidepressants, re-
gardless of the kind of drugs used.  For ex-
ample, Samson, et al. (24) examined the ac-
tivity of sgACC in predicting treatment 
response to mirtazapine or venlafaxine. A 
pre-treatment greater activation in the cin-
gulate cortex predicted the greater clinical 
response to the drugs studied.  Other re-
search revealed similar results, that ACC 
activity serves as a strongest predictive val-
ue in predicting treatment response to cital-
opram—another type of antidepressant (25), 
and to fluoxetine, the most common antide-
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pressant prescribed (26). Consistently, these 
studies demonstrate that patients with 
greater functional activation of anterior cin-
gulate cortex would have faster improve-
ment with pharmacological antidepressant. 
Most of them drew on their conclusion 
from a small sample (N = 17 to 20 patients 
with balanced control), but given the 
observed consistency and high replicability, 
this finding can potentially be utilised to 
establish a clinical biomarker. 
A meta-analysis did confirm the find-
ings and suggested that ACC activity and 
hippocampal volume have potential 
significance to be developed into a 
prognostic marker in depression treatment 
(27). However, the authors only considered 
standard psychotherapy and 
pharmacotherapy in their inclusion criteria, 
thus, excluding the possibility of ACC 
prediction of treatment response in other 
therapies, such as deep-brain stimulation, 
transcranial magnetic stimulation, as well 
as augmentation of drug with cognitive be-
havior therapy (28).  
Interestingly, a number of studies re-
ported that a decrease in sgACC activity 
correlated with a better outcome if treated 
with psychotherapy (such as cognitive be-
havior therapy, CBT) rather than pharma-
cologic antidepressant. Siegle, Carter (29) 
prospectively studied 14 medication-free 
subjects with depression who were about to 
undergo CBT. They found that those with 
hypoactive sgACC (Brodmann’s area 25) 
would respond better to CBT. A notion 
should be made that this group used a high-
er-power fMRI scanner (3 Tesla).  Fu, et al. 
(30) failed to replicate their findings when 
using 1,5 Tesla scanner. Instead, they found 
the correlation in dorsal anterior cingulate 
rather than sgACC. A similar study with 
PET (31), on the other hand, was consistent 
with the finding by Siegle and colleagues, 
supporting that hypoactivity of sgACC, 
rather than dorsal ACC is more likely to be 
associated with better response to CBT.  
More recently, Argyelan et al. (32) ob-
served that electroconvulsive therapy 
(ECT) can have an antidepressant effect, 
which can be predicted by SCC relative 
underactivity. Richey, et al. (33) also exam-
ined the effectiveness of CBT in patients 
with depression (N=22) based on their neu-
ral activity, focusing on the ventral and 
dorsal prefrontal cortex. Intriguingly, they 
found the opposite effect, in which hyper-
activity, rather than hypoactivity, observed 
in the ventromedial prefrontal cortex is pre-
dictive to the success of subsequent CBT. 
This inconsistency—not only in this case, 
but also across fMRI publications—can be 
due to differences in the region of interest 
(ROI), baseline calibration of the appa-
ratus, voxel clustering, and the choosing of 
statistical threshold (34, 35). Most of the stud-
ies involved small sample group, therefore, 
limited their power and generalisability (27, 
34). Interestingly, using whole-genome ex-
pression analysis, Barthas, et al. (36) have 
discovered a particular molecule called mi-
togen-activated protein kinase phosphatase
-1 which is epigenetically upregulated in a 
cingulate area during depression in an ani-
mal model. This, together with the clinical 
findings, reinforced the pivotal role of the 
cingulate in depression pathogenesis.  
 
SUMMARY 
In summary, the hyperactivity of 
sgACC can be a potential biomarker to pre-
dict the risk of individuals suffering from 
depression. By identifying those who are at 
risk of developing psychiatric disorders, 
actions could be made to prevent educa-
tional failure and socio-economical compli-
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cations, or in other words, allowing further 
step in providing mental-health assistance 
to be taken (37). The workup with the Clini-
cal Staging Model developed by Hickie, et 
al. (38) would also be benefited by the intro-
duction of biomarkers, especially in identi-
fying those who have risk factors for de-
pression, where sgACC could serve as a 
likely candidate.  
In terms of predicting treatment re-
sponse, the distinction between medication-
respondent and psychotherapy-respondent 
also could be drawn based on sgACC activ-
ity, although further research is still needed. 
This unique property of sgACC functional 
activity could encourage the division of de-
pressive disorders based on their potential 
response to treatment. Once established, 
clinicians will have a pre-treatment guide to 
start medication, which is much better than 
doing trial-and-error and watchful waiting 
for weeks before deciding to switch or 
modify the therapy (39). However, learning 
from previous quests for biomarkers, a 
standardized examination and interpretation 
should be made prior to its application in 
clinical setting to prevent false-positive 
findings (40). 
Finally, there has been also a concern 
that a predictive biomarker should be able 
to show accuracy in individual level (27). 
Certainly, further research in this area is 
mandatory, involving larger samples and 
more standardized protocol as well as sta-
tistical methods. A very good lesson can be 
taken from genomic biomarkers, where a 
guideline for assessing clinical significance 
has been developed (41). The translation of 
statistical significance to clinical signifi-
cance would be necessary, especially in 
predicting the prognostic value, because 
virtually all fMRI studies can only report 
the statistical significance. 
To increase the specificity and sensi-
tivity to a diagnosis, a combination of two 
potential biomarkers can also be consid-
ered. For example, by combining a neu-
roimaging biomarker with some neuropsy-
chological portraits (42) or by combining 
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